nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR3—prostate gland—urinary bladder cancer	0.0449	0.165	CbGeAlD
Dantrolene—RYR3—seminal vesicle—urinary bladder cancer	0.038	0.139	CbGeAlD
Dantrolene—RYR1—prostate gland—urinary bladder cancer	0.0322	0.118	CbGeAlD
Dantrolene—RYR3—smooth muscle tissue—urinary bladder cancer	0.0318	0.117	CbGeAlD
Dantrolene—Nitrofurantoin—POR—urinary bladder cancer	0.031	1	CrCbGaD
Dantrolene—RYR3—female reproductive system—urinary bladder cancer	0.0245	0.09	CbGeAlD
Dantrolene—RYR1—smooth muscle tissue—urinary bladder cancer	0.0228	0.0837	CbGeAlD
Dantrolene—RYR3—vagina—urinary bladder cancer	0.0222	0.0814	CbGeAlD
Dantrolene—RYR1—female reproductive system—urinary bladder cancer	0.0176	0.0646	CbGeAlD
Dantrolene—RYR1—vagina—urinary bladder cancer	0.0159	0.0584	CbGeAlD
Dantrolene—CYP3A4—urine—urinary bladder cancer	0.0156	0.0573	CbGeAlD
Dantrolene—RYR3—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00494	0.104	CbGpPWpGaD
Dantrolene—CYP3A4—renal system—urinary bladder cancer	0.00381	0.014	CbGeAlD
Dantrolene—RYR1—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00364	0.0768	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—TRPV1—urinary bladder cancer	0.00322	0.068	CbGpPWpGaD
Dantrolene—CYP3A4—female reproductive system—urinary bladder cancer	0.00305	0.0112	CbGeAlD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00283	0.0598	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IGFBP3—urinary bladder cancer	0.00246	0.052	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—TRPV1—urinary bladder cancer	0.00237	0.0501	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—FAS—urinary bladder cancer	0.00235	0.0497	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.0019	0.0402	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IGFBP3—urinary bladder cancer	0.00182	0.0384	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00148	0.0313	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.0014	0.0296	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00138	0.029	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00131	0.0276	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00112	0.0237	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00106	0.0224	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00101	0.0214	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TNF—urinary bladder cancer	0.001	0.0211	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000933	0.0197	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TP53—urinary bladder cancer	0.000881	0.0186	CbGpPWpGaD
Dantrolene—Diplopia—Doxorubicin—urinary bladder cancer	0.000856	0.00132	CcSEcCtD
Dantrolene—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000856	0.00132	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000851	0.00131	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—urinary bladder cancer	0.000846	0.0013	CcSEcCtD
Dantrolene—Insomnia—Fluorouracil—urinary bladder cancer	0.000845	0.0013	CcSEcCtD
Dantrolene—Somnolence—Gemcitabine—urinary bladder cancer	0.000845	0.0013	CcSEcCtD
Dantrolene—Anorexia—Cisplatin—urinary bladder cancer	0.000844	0.0013	CcSEcCtD
Dantrolene—Discomfort—Etoposide—urinary bladder cancer	0.000836	0.00129	CcSEcCtD
Dantrolene—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000832	0.00128	CcSEcCtD
Dantrolene—Somnolence—Fluorouracil—urinary bladder cancer	0.000831	0.00128	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000826	0.0174	CbGpPWpGaD
Dantrolene—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000826	0.00127	CcSEcCtD
Dantrolene—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000823	0.00127	CcSEcCtD
Dantrolene—Fatigue—Gemcitabine—urinary bladder cancer	0.000819	0.00126	CcSEcCtD
Dantrolene—Confusional state—Etoposide—urinary bladder cancer	0.000818	0.00126	CcSEcCtD
Dantrolene—Muscular weakness—Epirubicin—urinary bladder cancer	0.000816	0.00126	CcSEcCtD
Dantrolene—Constipation—Gemcitabine—urinary bladder cancer	0.000813	0.00125	CcSEcCtD
Dantrolene—Pain—Gemcitabine—urinary bladder cancer	0.000813	0.00125	CcSEcCtD
Dantrolene—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000812	0.00125	CcSEcCtD
Dantrolene—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000812	0.00125	CcSEcCtD
Dantrolene—Asthenia—Thiotepa—urinary bladder cancer	0.000811	0.00125	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000807	0.00124	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000802	0.0169	CbGpPWpGaD
Dantrolene—Dysphagia—Epirubicin—urinary bladder cancer	0.0008	0.00123	CcSEcCtD
Dantrolene—Pruritus—Thiotepa—urinary bladder cancer	0.000799	0.00123	CcSEcCtD
Dantrolene—Pain—Fluorouracil—urinary bladder cancer	0.000799	0.00123	CcSEcCtD
Dantrolene—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000795	0.00122	CcSEcCtD
Dantrolene—Tachycardia—Etoposide—urinary bladder cancer	0.000792	0.00122	CcSEcCtD
Dantrolene—Eosinophilia—Epirubicin—urinary bladder cancer	0.000792	0.00122	CcSEcCtD
Dantrolene—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000785	0.00121	CcSEcCtD
Dantrolene—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000783	0.00121	CcSEcCtD
Dantrolene—Anorexia—Etoposide—urinary bladder cancer	0.000774	0.00119	CcSEcCtD
Dantrolene—Diarrhoea—Thiotepa—urinary bladder cancer	0.000773	0.00119	CcSEcCtD
Dantrolene—Decreased appetite—Cisplatin—urinary bladder cancer	0.00077	0.00119	CcSEcCtD
Dantrolene—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00077	0.00119	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—urinary bladder cancer	0.000762	0.00117	CcSEcCtD
Dantrolene—Depression—Methotrexate—urinary bladder cancer	0.00076	0.00117	CcSEcCtD
Dantrolene—Pain—Cisplatin—urinary bladder cancer	0.000758	0.00117	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000757	0.016	CbGpPWpGaD
Dantrolene—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000755	0.00116	CcSEcCtD
Dantrolene—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000751	0.00116	CcSEcCtD
Dantrolene—Renal failure—Methotrexate—urinary bladder cancer	0.000749	0.00115	CcSEcCtD
Dantrolene—Dizziness—Thiotepa—urinary bladder cancer	0.000747	0.00115	CcSEcCtD
Dantrolene—Urticaria—Fluorouracil—urinary bladder cancer	0.000742	0.00114	CcSEcCtD
Dantrolene—Dysphagia—Doxorubicin—urinary bladder cancer	0.00074	0.00114	CcSEcCtD
Dantrolene—Pollakiuria—Epirubicin—urinary bladder cancer	0.000739	0.00114	CcSEcCtD
Dantrolene—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000739	0.00114	CcSEcCtD
Dantrolene—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000733	0.00113	CcSEcCtD
Dantrolene—Sweating—Methotrexate—urinary bladder cancer	0.000731	0.00113	CcSEcCtD
Dantrolene—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00073	0.00112	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—urinary bladder cancer	0.000727	0.00112	CcSEcCtD
Dantrolene—Somnolence—Etoposide—urinary bladder cancer	0.000722	0.00111	CcSEcCtD
Dantrolene—Vomiting—Thiotepa—urinary bladder cancer	0.000718	0.00111	CcSEcCtD
Dantrolene—Drowsiness—Epirubicin—urinary bladder cancer	0.000713	0.0011	CcSEcCtD
Dantrolene—Rash—Thiotepa—urinary bladder cancer	0.000712	0.0011	CcSEcCtD
Dantrolene—Dermatitis—Thiotepa—urinary bladder cancer	0.000712	0.0011	CcSEcCtD
Dantrolene—Headache—Thiotepa—urinary bladder cancer	0.000708	0.00109	CcSEcCtD
Dantrolene—Decreased appetite—Etoposide—urinary bladder cancer	0.000706	0.00109	CcSEcCtD
Dantrolene—Renal failure—Epirubicin—urinary bladder cancer	0.000701	0.00108	CcSEcCtD
Dantrolene—Body temperature increased—Cisplatin—urinary bladder cancer	0.0007	0.00108	CcSEcCtD
Dantrolene—Fatigue—Etoposide—urinary bladder cancer	0.0007	0.00108	CcSEcCtD
Dantrolene—Pain—Etoposide—urinary bladder cancer	0.000694	0.00107	CcSEcCtD
Dantrolene—Constipation—Etoposide—urinary bladder cancer	0.000694	0.00107	CcSEcCtD
Dantrolene—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000689	0.00106	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—urinary bladder cancer	0.000688	0.00106	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—urinary bladder cancer	0.000684	0.00105	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—urinary bladder cancer	0.000684	0.00105	CcSEcCtD
Dantrolene—Sweating—Epirubicin—urinary bladder cancer	0.000684	0.00105	CcSEcCtD
Dantrolene—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000684	0.00105	CcSEcCtD
Dantrolene—Asthenia—Gemcitabine—urinary bladder cancer	0.000682	0.00105	CcSEcCtD
Dantrolene—Haematuria—Epirubicin—urinary bladder cancer	0.00068	0.00105	CcSEcCtD
Dantrolene—Pruritus—Gemcitabine—urinary bladder cancer	0.000672	0.00104	CcSEcCtD
Dantrolene—Nausea—Thiotepa—urinary bladder cancer	0.000671	0.00103	CcSEcCtD
Dantrolene—Feeling abnormal—Etoposide—urinary bladder cancer	0.000669	0.00103	CcSEcCtD
Dantrolene—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000664	0.00102	CcSEcCtD
Dantrolene—Pruritus—Fluorouracil—urinary bladder cancer	0.000661	0.00102	CcSEcCtD
Dantrolene—Drowsiness—Doxorubicin—urinary bladder cancer	0.00066	0.00102	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—urinary bladder cancer	0.000659	0.00102	CcSEcCtD
Dantrolene—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000653	0.001	CcSEcCtD
Dantrolene—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00065	0.001	CcSEcCtD
Dantrolene—Renal failure—Doxorubicin—urinary bladder cancer	0.000649	0.000999	CcSEcCtD
Dantrolene—Urticaria—Etoposide—urinary bladder cancer	0.000645	0.000993	CcSEcCtD
Dantrolene—Haemoglobin—Epirubicin—urinary bladder cancer	0.000644	0.000991	CcSEcCtD
Dantrolene—Abdominal pain—Etoposide—urinary bladder cancer	0.000642	0.000988	CcSEcCtD
Dantrolene—Body temperature increased—Etoposide—urinary bladder cancer	0.000642	0.000988	CcSEcCtD
Dantrolene—Haemorrhage—Epirubicin—urinary bladder cancer	0.00064	0.000986	CcSEcCtD
Dantrolene—Hepatitis—Epirubicin—urinary bladder cancer	0.00064	0.000986	CcSEcCtD
Dantrolene—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000639	0.000984	CcSEcCtD
Dantrolene—Asthenia—Cisplatin—urinary bladder cancer	0.000636	0.000979	CcSEcCtD
Dantrolene—Sweating—Doxorubicin—urinary bladder cancer	0.000633	0.000974	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—urinary bladder cancer	0.000629	0.000969	CcSEcCtD
Dantrolene—Dizziness—Fluorouracil—urinary bladder cancer	0.000618	0.000951	CcSEcCtD
Dantrolene—Visual impairment—Epirubicin—urinary bladder cancer	0.000617	0.00095	CcSEcCtD
Dantrolene—Chills—Methotrexate—urinary bladder cancer	0.000614	0.000945	CcSEcCtD
Dantrolene—Diarrhoea—Cisplatin—urinary bladder cancer	0.000606	0.000933	CcSEcCtD
Dantrolene—Vomiting—Gemcitabine—urinary bladder cancer	0.000604	0.00093	CcSEcCtD
Dantrolene—Rash—Gemcitabine—urinary bladder cancer	0.000599	0.000923	CcSEcCtD
Dantrolene—Dermatitis—Gemcitabine—urinary bladder cancer	0.000599	0.000922	CcSEcCtD
Dantrolene—Hypersensitivity—Etoposide—urinary bladder cancer	0.000598	0.000921	CcSEcCtD
Dantrolene—Erythema—Methotrexate—urinary bladder cancer	0.000596	0.000917	CcSEcCtD
Dantrolene—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000596	0.000917	CcSEcCtD
Dantrolene—Headache—Gemcitabine—urinary bladder cancer	0.000595	0.000917	CcSEcCtD
Dantrolene—Flushing—Epirubicin—urinary bladder cancer	0.000594	0.000915	CcSEcCtD
Dantrolene—Vomiting—Fluorouracil—urinary bladder cancer	0.000594	0.000915	CcSEcCtD
Dantrolene—Hepatitis—Doxorubicin—urinary bladder cancer	0.000593	0.000912	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000593	0.000912	CcSEcCtD
Dantrolene—Rash—Fluorouracil—urinary bladder cancer	0.000589	0.000907	CcSEcCtD
Dantrolene—Dermatitis—Fluorouracil—urinary bladder cancer	0.000589	0.000906	CcSEcCtD
Dantrolene—Headache—Fluorouracil—urinary bladder cancer	0.000585	0.000901	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—urinary bladder cancer	0.000583	0.000898	CcSEcCtD
Dantrolene—Asthenia—Etoposide—urinary bladder cancer	0.000582	0.000897	CcSEcCtD
Dantrolene—Back pain—Methotrexate—urinary bladder cancer	0.000576	0.000887	CcSEcCtD
Dantrolene—Chills—Epirubicin—urinary bladder cancer	0.000575	0.000885	CcSEcCtD
Dantrolene—Pruritus—Etoposide—urinary bladder cancer	0.000574	0.000884	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000572	0.0121	CbGpPWpGaD
Dantrolene—Visual impairment—Doxorubicin—urinary bladder cancer	0.000571	0.000879	CcSEcCtD
Dantrolene—Nausea—Gemcitabine—urinary bladder cancer	0.000565	0.000869	CcSEcCtD
Dantrolene—Vomiting—Cisplatin—urinary bladder cancer	0.000563	0.000867	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—urinary bladder cancer	0.000561	0.000864	CcSEcCtD
Dantrolene—Rash—Cisplatin—urinary bladder cancer	0.000559	0.00086	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000558	0.0118	CbGpPWpGaD
Dantrolene—Dermatitis—Cisplatin—urinary bladder cancer	0.000558	0.000859	CcSEcCtD
Dantrolene—Erythema—Epirubicin—urinary bladder cancer	0.000557	0.000858	CcSEcCtD
Dantrolene—Diarrhoea—Etoposide—urinary bladder cancer	0.000555	0.000855	CcSEcCtD
Dantrolene—Nausea—Fluorouracil—urinary bladder cancer	0.000555	0.000855	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000553	0.000851	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—urinary bladder cancer	0.000551	0.000848	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—urinary bladder cancer	0.00055	0.000847	CcSEcCtD
Dantrolene—Tension—Epirubicin—urinary bladder cancer	0.000547	0.000842	CcSEcCtD
Dantrolene—Dysgeusia—Epirubicin—urinary bladder cancer	0.000546	0.00084	CcSEcCtD
Dantrolene—Nervousness—Epirubicin—urinary bladder cancer	0.000541	0.000834	CcSEcCtD
Dantrolene—Back pain—Epirubicin—urinary bladder cancer	0.000539	0.00083	CcSEcCtD
Dantrolene—Malaise—Methotrexate—urinary bladder cancer	0.000537	0.000827	CcSEcCtD
Dantrolene—Dizziness—Etoposide—urinary bladder cancer	0.000537	0.000826	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—urinary bladder cancer	0.000533	0.000821	CcSEcCtD
Dantrolene—Chills—Doxorubicin—urinary bladder cancer	0.000532	0.000819	CcSEcCtD
Dantrolene—Nausea—Cisplatin—urinary bladder cancer	0.000526	0.00081	CcSEcCtD
Dantrolene—Vision blurred—Epirubicin—urinary bladder cancer	0.000525	0.000809	CcSEcCtD
Dantrolene—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000517	0.000796	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—urinary bladder cancer	0.000516	0.000795	CcSEcCtD
Dantrolene—Vomiting—Etoposide—urinary bladder cancer	0.000516	0.000795	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—urinary bladder cancer	0.000516	0.000794	CcSEcCtD
Dantrolene—Anaemia—Epirubicin—urinary bladder cancer	0.000515	0.000793	CcSEcCtD
Dantrolene—Rash—Etoposide—urinary bladder cancer	0.000512	0.000788	CcSEcCtD
Dantrolene—Dermatitis—Etoposide—urinary bladder cancer	0.000511	0.000787	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000509	0.0107	CbGpPWpGaD
Dantrolene—Headache—Etoposide—urinary bladder cancer	0.000508	0.000783	CcSEcCtD
Dantrolene—Myalgia—Methotrexate—urinary bladder cancer	0.000507	0.000781	CcSEcCtD
Dantrolene—Tension—Doxorubicin—urinary bladder cancer	0.000506	0.000779	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000505	0.000778	CcSEcCtD
Dantrolene—Malaise—Epirubicin—urinary bladder cancer	0.000503	0.000774	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000502	0.0106	CbGpPWpGaD
Dantrolene—Discomfort—Methotrexate—urinary bladder cancer	0.000501	0.000771	CcSEcCtD
Dantrolene—Nervousness—Doxorubicin—urinary bladder cancer	0.000501	0.000771	CcSEcCtD
Dantrolene—Leukopenia—Epirubicin—urinary bladder cancer	0.000499	0.000768	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—urinary bladder cancer	0.000499	0.000768	CcSEcCtD
Dantrolene—Confusional state—Methotrexate—urinary bladder cancer	0.00049	0.000755	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000486	0.000748	CcSEcCtD
Dantrolene—Vision blurred—Doxorubicin—urinary bladder cancer	0.000486	0.000748	CcSEcCtD
Dantrolene—Convulsion—Epirubicin—urinary bladder cancer	0.000483	0.000744	CcSEcCtD
Dantrolene—Nausea—Etoposide—urinary bladder cancer	0.000482	0.000742	CcSEcCtD
Dantrolene—Hypertension—Epirubicin—urinary bladder cancer	0.000481	0.000741	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000479	0.000737	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—urinary bladder cancer	0.000477	0.000734	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000476	0.000733	CcSEcCtD
Dantrolene—Myalgia—Epirubicin—urinary bladder cancer	0.000475	0.000731	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00047	0.000724	CcSEcCtD
Dantrolene—Discomfort—Epirubicin—urinary bladder cancer	0.000469	0.000722	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—urinary bladder cancer	0.000465	0.000716	CcSEcCtD
Dantrolene—Dry mouth—Epirubicin—urinary bladder cancer	0.000464	0.000715	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—urinary bladder cancer	0.000463	0.000713	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—urinary bladder cancer	0.000462	0.000711	CcSEcCtD
Dantrolene—Confusional state—Epirubicin—urinary bladder cancer	0.000459	0.000706	CcSEcCtD
Dantrolene—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000455	0.0007	CcSEcCtD
Dantrolene—Convulsion—Doxorubicin—urinary bladder cancer	0.000447	0.000688	CcSEcCtD
Dantrolene—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000445	0.000686	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—urinary bladder cancer	0.000445	0.000686	CcSEcCtD
Dantrolene—Tachycardia—Epirubicin—urinary bladder cancer	0.000444	0.000684	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000443	0.000682	CcSEcCtD
Dantrolene—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00044	0.000677	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—urinary bladder cancer	0.00044	0.000677	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—urinary bladder cancer	0.000439	0.000676	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000438	0.00925	CbGpPWpGaD
Dantrolene—Discomfort—Doxorubicin—urinary bladder cancer	0.000434	0.000668	CcSEcCtD
Dantrolene—Anorexia—Epirubicin—urinary bladder cancer	0.000434	0.000668	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—urinary bladder cancer	0.000432	0.000665	CcSEcCtD
Dantrolene—Dry mouth—Doxorubicin—urinary bladder cancer	0.000429	0.000661	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—urinary bladder cancer	0.000428	0.000659	CcSEcCtD
Dantrolene—Confusional state—Doxorubicin—urinary bladder cancer	0.000424	0.000654	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—urinary bladder cancer	0.000423	0.000651	CcSEcCtD
Dantrolene—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000421	0.000648	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—urinary bladder cancer	0.000419	0.000645	CcSEcCtD
Dantrolene—Pain—Methotrexate—urinary bladder cancer	0.000416	0.00064	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000414	0.000638	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000413	0.00871	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000412	0.000635	CcSEcCtD
Dantrolene—Insomnia—Epirubicin—urinary bladder cancer	0.000411	0.000634	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000411	0.00868	CbGpPWpGaD
Dantrolene—Tachycardia—Doxorubicin—urinary bladder cancer	0.000411	0.000633	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000407	0.000627	CcSEcCtD
Dantrolene—Somnolence—Epirubicin—urinary bladder cancer	0.000404	0.000623	CcSEcCtD
Dantrolene—Anorexia—Doxorubicin—urinary bladder cancer	0.000401	0.000618	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000401	0.000617	CcSEcCtD
Dantrolene—Dyspepsia—Epirubicin—urinary bladder cancer	0.0004	0.000617	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000398	0.000612	CcSEcCtD
Dantrolene—Decreased appetite—Epirubicin—urinary bladder cancer	0.000395	0.000609	CcSEcCtD
Dantrolene—Fatigue—Epirubicin—urinary bladder cancer	0.000392	0.000604	CcSEcCtD
Dantrolene—Pain—Epirubicin—urinary bladder cancer	0.000389	0.000599	CcSEcCtD
Dantrolene—Constipation—Epirubicin—urinary bladder cancer	0.000389	0.000599	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—urinary bladder cancer	0.000386	0.000595	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—urinary bladder cancer	0.000384	0.000592	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—urinary bladder cancer	0.000384	0.000592	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000384	0.00059	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—urinary bladder cancer	0.000381	0.000586	CcSEcCtD
Dantrolene—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000375	0.000577	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—urinary bladder cancer	0.000374	0.000576	CcSEcCtD
Dantrolene—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000372	0.000573	CcSEcCtD
Dantrolene—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000371	0.000571	CcSEcCtD
Dantrolene—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000366	0.000563	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—urinary bladder cancer	0.000363	0.000559	CcSEcCtD
Dantrolene—Urticaria—Epirubicin—urinary bladder cancer	0.000361	0.000556	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—urinary bladder cancer	0.00036	0.000554	CcSEcCtD
Dantrolene—Pain—Doxorubicin—urinary bladder cancer	0.00036	0.000554	CcSEcCtD
Dantrolene—Abdominal pain—Epirubicin—urinary bladder cancer	0.00036	0.000554	CcSEcCtD
Dantrolene—Body temperature increased—Epirubicin—urinary bladder cancer	0.00036	0.000554	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000358	0.000551	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000354	0.00748	CbGpPWpGaD
Dantrolene—Asthenia—Methotrexate—urinary bladder cancer	0.000349	0.000537	CcSEcCtD
Dantrolene—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000347	0.000534	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000344	0.00053	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—urinary bladder cancer	0.000344	0.00053	CcSEcCtD
Dantrolene—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000335	0.000516	CcSEcCtD
Dantrolene—Urticaria—Doxorubicin—urinary bladder cancer	0.000334	0.000515	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000333	0.000512	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000333	0.000512	CcSEcCtD
Dantrolene—Diarrhoea—Methotrexate—urinary bladder cancer	0.000333	0.000512	CcSEcCtD
Dantrolene—Asthenia—Epirubicin—urinary bladder cancer	0.000326	0.000503	CcSEcCtD
Dantrolene—Pruritus—Epirubicin—urinary bladder cancer	0.000322	0.000496	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—urinary bladder cancer	0.000321	0.000495	CcSEcCtD
Dantrolene—Diarrhoea—Epirubicin—urinary bladder cancer	0.000311	0.000479	CcSEcCtD
Dantrolene—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00031	0.000478	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—urinary bladder cancer	0.000309	0.000476	CcSEcCtD
Dantrolene—Rash—Methotrexate—urinary bladder cancer	0.000307	0.000472	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—urinary bladder cancer	0.000306	0.000471	CcSEcCtD
Dantrolene—Headache—Methotrexate—urinary bladder cancer	0.000305	0.000469	CcSEcCtD
Dantrolene—Asthenia—Doxorubicin—urinary bladder cancer	0.000302	0.000465	CcSEcCtD
Dantrolene—Dizziness—Epirubicin—urinary bladder cancer	0.000301	0.000463	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—urinary bladder cancer	0.000298	0.000459	CcSEcCtD
Dantrolene—Vomiting—Epirubicin—urinary bladder cancer	0.000289	0.000445	CcSEcCtD
Dantrolene—Nausea—Methotrexate—urinary bladder cancer	0.000289	0.000445	CcSEcCtD
Dantrolene—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000288	0.000443	CcSEcCtD
Dantrolene—Rash—Epirubicin—urinary bladder cancer	0.000287	0.000442	CcSEcCtD
Dantrolene—Dermatitis—Epirubicin—urinary bladder cancer	0.000287	0.000441	CcSEcCtD
Dantrolene—Headache—Epirubicin—urinary bladder cancer	0.000285	0.000439	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000281	0.00593	CbGpPWpGaD
Dantrolene—Dizziness—Doxorubicin—urinary bladder cancer	0.000278	0.000429	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000277	0.00585	CbGpPWpGaD
Dantrolene—Nausea—Epirubicin—urinary bladder cancer	0.00027	0.000416	CcSEcCtD
Dantrolene—Vomiting—Doxorubicin—urinary bladder cancer	0.000268	0.000412	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000266	0.00562	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000266	0.00562	CbGpPWpGaD
Dantrolene—Rash—Doxorubicin—urinary bladder cancer	0.000265	0.000409	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—urinary bladder cancer	0.000265	0.000408	CcSEcCtD
Dantrolene—Headache—Doxorubicin—urinary bladder cancer	0.000264	0.000406	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000262	0.00554	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000261	0.00552	CbGpPWpGaD
Dantrolene—Nausea—Doxorubicin—urinary bladder cancer	0.00025	0.000385	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000243	0.00514	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00024	0.00507	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000219	0.00463	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000216	0.00456	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000189	0.00399	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000146	0.00308	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000144	0.00304	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000117	0.00246	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000113	0.00239	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.84e-05	0.00165	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.73e-05	0.00163	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.2e-05	0.00152	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.1e-05	0.0015	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.8e-05	0.00101	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.55e-05	0.000961	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.55e-05	0.000961	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.16e-05	0.000879	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.75e-05	0.000791	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.54e-05	0.000747	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.45e-05	0.000728	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.76e-05	0.000582	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.49e-05	0.000526	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.15e-05	0.000454	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.99e-05	0.000421	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.99e-05	0.000421	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.93e-05	0.000408	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.61e-05	0.000339	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	0.000283	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.25e-05	0.000263	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	0.00026	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	0.00026	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.18e-05	0.000249	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	0.000244	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	0.00023	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.83e-06	0.000186	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.48e-06	0.000179	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.94e-06	0.000147	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.05e-06	0.000128	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.77e-06	0.000122	CbGpPWpGaD
